一般演題（口演）15 EGFR遺伝子変異陽性肺癌（臨床試験）

[O15-2] Telisotuzumab Vedotin and Osimertinib in Patients With EGFR-Mutated（MT）, c-Met Overexpressing NSCLC

^○Hidehito Horinouchi¹, D. Ross Camidge², Shun Lu³, Pascale Tomasini⁴, Penelope Bradbury⁵, Michael Oh⁶, Jenny G. Parvani⁷, P. K. Epling-Burnette⁷, Izhar Batth⁷, Ronald Pandoy⁷, Weihua Shi⁷, Summer Xia⁷, Christine K. Ratajczak⁷, Vincent Blot⁷, Jonathan Goldman⁶ (1.National Cancer Center Hospital, Tokyo, Japan, 2.University of Colorado Cancer Center, Aurora, CO, USA, 3.Shanghai Chest Hospital, School of Medicine, Shanghai, China, 4.Hôpitaux Universitaires de Marseille Timone, Marseille, France, 5.Princess Margaret Cancer Centre, Toronto, ON, Canada, 6.David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA, 7.AbbVie Inc, North Chicago, IL, USA)

アンコール演題